The Evolving Treatment Options for Diabetic Macular Edema

Table 3

Summary of major studies evaluating anti-VEGF medications for DME.

Reference	Study name	Follow-up	Type of DME	Type of study	Study methodology	Number of treatments	Mean ETDRS letter gains	Number of eyes
[53]	RIDE	24 months	CMT OCT ≥ 275 μm	Prospective, multicenter, Phase 3	Sham	1.6 laser	2.3	130
					0.3 mg lucentis	20.5 IVI; 0.7 laser	10.9	125
					0.5 mg lucentis	21.9 IVI; 0.3 laser	12	127
					Note: rescue laser after month 3
[53]	RISE	24 months	CMT OCT ≥ 275 μm	Prospective, multicenter, Phase 3	Sham	1.8 laser	2.6	127
					0.3 mg lucentis	21.5 IVI; 0.8 laser	12.5	125
					0.5 mg lucentis	20.9 IVI; 0.8 laser	11.9	125
					Note: rescue laser after month 3
[54]	RESTORE	12 months	fDME and dDME	Prospective, multicenter, Phase 3	lucentis + sham laser	7 IVI	6.1	116
					Lucentis + laser	6.8 IVI; 1.7 laser	5.9	118
					Sham lucentis + laser	2.1 laser	0.8	111
[55]	READ-2	6 months	CMT OCT ≥ 250 μm	Prospective, multicenter, Phase 2	Lucentis alone	4	7.2	42
			dDME and fDME		Laser alone	1.8	−0.4	42
					Lucentis + laser	2 IVI; 2 laser	3.8	42
[56]	READ-2	24 months	CMT OCT ≥ 250 μm		Lucentis alone	9.3	7.7	33
		Above study [55] + 18 months	dDME and fDME	Prospective, multicenter, Phase 2	Laser alone; delayed lucentis	4.4 IVI; 1.8 laser	5.1	34
		+18 months			Lucentis + laser	4.9 IVI; 2 laser	6.8	34
[57]	RESOLVE	12 months	CMT OCT ≥ 300 μm	Prospective, multicenter, phase 2	Lucentis	10.2	10.3	102
					Sham (no medication injected)	8.9 (sham treatments)	−1.4	49
					Note: rescue laser for both groups
[58]	DA-VINCI	12 months	CMT OCT ≥ 250 μm	Prospective, multicenter, Phase 2	Eylea (all arms combined)	9.3 IVI; 0.7 laser	9.7 to 13.1	175
					Laser alone	2.5	−1.3	44
					Note: rescue laser after month 6
[59]	DRCR Protocol I: lucentis versus prompt or deferred laser	36 months	ciDME	Prospective, multicenter	0.5 mg lucentis + prompt laser	12 IVI; ≥ 1 laser, 100%	6.8	144
					0.5 mg lucentis + deferred laser	15 IVI; ≥ 1 laser, 46%	9.7	147
[40]	BOLT	24 months	CMT OCT ≥ 270 μm persistent ciDME	Prospective, single center	Avastin alone	13 IVI	8.6	37
					Laser alone	4 laser	−0.5	28
[41]	PACORS	24 months	dDME	Retrospective, multicenter	Avastin alone	5.8	11.8	141
					Laser alone	2.2	4.8	120
					Avastin + laser	6.2 IVI*; 1 laser	8.2	157

*IVI: Intravitreal injection.